The bone marrow transplant market is anticipated to flourish at an average CAGR of 3.4% between 2023 and 2033. The market is expected to hold a market share of US$ 14.86 billion by 2033, while the market is likely to reach a value of US$ 10.65 billion in 2023. A historical CAGR of 2.5% has been recorded by the experts of Future Market Insights for the market concerned.
The hematopoietic stem cell is a soft vascular tissue in the interiors of long bones, and a bone marrow transplant is identified as the procedure to replace the damaged or destroyed bone marrow with healthy bone marrow stem cells.
| Attributes | Details |
|---|---|
| Bone Marrow Transplant Market CAGR (2023 to 2033) | 3.4% |
| Bone Marrow Transplant Market Size (2023) | US$ 10.65 billion |
| Bone Marrow Transplant Market Size (2033) | US$ 14.86 billion |
The bone marrow transplant procedure is prescribed for the treatment of advanced stages of leukemia, Hodgkin, and non-Hodgkin lymphomas, multiple myeloma, aplastic and sickle cell anemia, thalassemia, and other diseases. Increasing awareness, combined with an increase in initiatives run by healthcare practitioners, is majorly responsible for the global growth of the market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market is anticipated to have mixed dynamics contributing to the bearish propulsion of the bone marrow transplant market. Several factors impacting the expansion of the market are identified during the study.
Besides the factors influencing growth, it is also identified that certain aspects can limit growth and curb the pace of growth further in the market.
Drivers:
Restraints:
| Country | Revenue Share % (2022) |
|---|---|
| United States | 30.3% |
| Germany | 11.9% |
| Japan | 2/0% |
| North America | 32.3% |
| Europe | 53.1% |
| Country | CAGR % (2023 to 2033) |
|---|---|
| China | 4.2% |
| India | 3.4% |
| United Kingdom | 2.4% |
| Australia | 3.1% |
North America is projected to secure steady bone marrow transplant market growth during the forecast period. The region cumulatively held 32.3% market share of the global bone marrow transplant market in 2022.
The factors attributing to the growth can be mentioned as follows:
Europe is projected to dominate the global market for bone marrow transplants during the forecast period. At present, Europe holds 53.1% of the total market share for bone marrow transplants worldwide in 2022.
The reasons owing for such extensive market expansion are mentioned below:
Principal Consultant
| Category | By Transplant Type |
|---|---|
| Leading Segment | Autologous |
| Market Share (2022) | 54.5% |
| Category | By End User |
|---|---|
| Leading Segment | Hospital |
| Market Share (2022) | 90.3% |
The start-ups in the bone marrow transplant market are indulging in collaborations and continually making innovations to stem cell transplant procedures to further make it convenient and cost-efficient for the population.
| Company Name | Magenta Therapeutics, Cambridge (United States) |
|---|---|
| Total Funding | US$ 151 million |
| Description | Developed stem cell-based therapies for autoimmune disease, genetic blood disorders, and cancer. The company has developed stem cell transplants by using targeted antibodies, stem cell harvesting using new biologic agents, and increasing stem cell numbers by targeting self-renewal pathways. |
| Company Name | Kiadis Pharma, Amsterdam (Netherlands) |
|---|---|
| Total Funding | US$ 33 million |
| Description | Kiadis Pharma is a developer of therapeutic solutions for hematopoietic stem cell transplants. It is focused on developing solutions for complications and limitations of hematopoietic stem cell transplants (HSCT) in blood cancer patients. The company uses all depleted T-cell immunotherapeutics (ATIR) to support the patient’s newly transplanted immune system before it becomes fully functional. This enables better acceptance of even haploidentical (or lower) stem cell donors. Kiadis is investigating the use of ATIR in leukemia and thalassemia. |
| Company Name | Talaris, Boston |
|---|---|
| Total Funding | US$ 215 million |
| Description | Talaris Therapeutics is involved in developing single-dose cell therapy to treat living donor kidney transplant tolerance. They have developed a proprietary technology that allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs). The lead candidate, FCR001, is in phase III clinical trial, which is being investigated for living donor kidney transplant tolerance. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The bone marrow transplant market is highly competitive and consists of several leading players. To increase their global market presence, market leaders are engaging in various product launches, mergers and acquisitions, and development activities focusing on orthopedic surgical treatments.
Recent Developments
Some Recent Developments Identified in the Analysis are:
The market is anticipated to be valued at US$ 10.65 billion in 2023.
The global market advanced at a 2.5% HCAGR from 2018 to 2022.
Up until 2033, the market is anticipated to thrive at a CAGR of 3.4%.
Potentially holding 32.3% of the market in North America.
The market has been dominated by Europe, 53.1%.
By 2033, the market is anticipated to be worth US$14.86 billion.
The autologous category to escalate to a market share of 54.5% in 2023.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Transplant Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Transplant Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Transplant Type, 2023 to 2033 5.3.1. Autologous 5.3.2. Allogeneic 5.4. Y-o-Y Growth Trend Analysis By Transplant Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Transplant Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033 6.3.1. Leukemia 6.3.2. Lymphoma 6.3.3. Myeloma 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End-User , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User , 2023 to 2033 7.3.1. Hospitals 7.3.2. Multispecialty Clinics 7.3.3. Ambulatory Surgical Centers 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By End-User , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End-User , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA. 9.2.1.2. Canada 9.2.2. By Transplant Type 9.2.3. By Disease Indication 9.2.4. By End-User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Transplant Type 9.3.3. By Disease Indication 9.3.4. By End-User 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Transplant Type 10.2.3. By Disease Indication 10.2.4. By End-User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Transplant Type 10.3.3. By Disease Indication 10.3.4. By End-User 10.4. Key Takeaways 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Transplant Type 11.2.3. By Disease Indication 11.2.4. By End-User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Transplant Type 11.3.3. By Disease Indication 11.3.4. By End-User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Transplant Type 12.2.3. By Disease Indication 12.2.4. By End-User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Transplant Type 12.3.3. By Disease Indication 12.3.4. By End-User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Transplant Type 13.2.3. By Disease Indication 13.2.4. By End-User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Transplant Type 13.3.3. By Disease Indication 13.3.4. By End-User 13.4. Key Takeaways 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Transplant Type 14.2.3. By Disease Indication 14.2.4. By End-User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Transplant Type 14.3.3. By Disease Indication 14.3.4. By End-User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Transplant Type 15.2.3. By Disease Indication 15.2.4. By End-User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Transplant Type 15.3.3. By Disease Indication 15.3.4. By End-User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Transplant Type 16.1.2.2. By Disease Indication 16.1.2.3. By End-User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Transplant Type 16.2.2.2. By Disease Indication 16.2.2.3. By End-User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Transplant Type 16.3.2.2. By Disease Indication 16.3.2.3. By End-User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Transplant Type 16.4.2.2. By Disease Indication 16.4.2.3. By End-User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Transplant Type 16.5.2.2. By Disease Indication 16.5.2.3. By End-User 16.6. United Kingdom. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Transplant Type 16.6.2.2. By Disease Indication 16.6.2.3. By End-User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Transplant Type 16.7.2.2. By Disease Indication 16.7.2.3. By End-User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Transplant Type 16.8.2.2. By Disease Indication 16.8.2.3. By End-User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Transplant Type 16.9.2.2. By Disease Indication 16.9.2.3. By End-User 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Transplant Type 16.10.2.2. By Disease Indication 16.10.2.3. By End-User 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Transplant Type 16.11.2.2. By Disease Indication 16.11.2.3. By End-User 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Transplant Type 16.12.2.2. By Disease Indication 16.12.2.3. By End-User 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Transplant Type 16.13.2.2. By Disease Indication 16.13.2.3. By End-User 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Transplant Type 16.14.2.2. By Disease Indication 16.14.2.3. By End-User 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Transplant Type 16.15.2.2. By Disease Indication 16.15.2.3. By End-User 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Transplant Type 16.16.2.2. By Disease Indication 16.16.2.3. By End-User 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Transplant Type 16.17.2.2. By Disease Indication 16.17.2.3. By End-User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Transplant Type 16.18.2.2. By Disease Indication 16.18.2.3. By End-User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Transplant Type 16.19.2.2. By Disease Indication 16.19.2.3. By End-User 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Transplant Type 16.20.2.2. By Disease Indication 16.20.2.3. By End-User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Transplant Type 16.21.2.2. By Disease Indication 16.21.2.3. By End-User 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Transplant Type 16.22.2.2. By Disease Indication 16.22.2.3. By End-User 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Transplant Type 16.23.2.2. By Disease Indication 16.23.2.3. By End-User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Transplant Type 17.3.3. By Disease Indication 17.3.4. By End-User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Lonza Group Ltd. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Merck Millipore Corporation 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Sanofi-Aventis LLC. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. AllCells LLC. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. STEMCELL Technologies 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. ATCC Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Hemacare Corporation 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Cellular Dynamics International 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. ReachBio LLC. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Conversant Bio, ABM Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. PromoCell GmbH 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. Cruline Human biospecimen PRO 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 18.1.13. Lifeline Cell Technology 18.1.13.1. Overview 18.1.13.2. Product Portfolio 18.1.13.3. Profitability by Market Segments 18.1.13.4. Sales Footprint 18.1.13.5. Strategy Overview 18.1.13.5.1. Marketing Strategy 18.1.14. Mesoblast Ltd. 18.1.14.1. Overview 18.1.14.2. Product Portfolio 18.1.14.3. Profitability by Market Segments 18.1.14.4. Sales Footprint 18.1.14.5. Strategy Overview 18.1.14.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Bone Marrow Transplant Market
